Age-Related Macular Degeneration (AMD)

• Age-Related Macular Degeneration (AMD) for Patients
• Impact of Anti-VEGF on Vision Outcomes in nAMD: 6-Year Analysis of the AAO IRIS® Registry
• TENAYA/LUCERNE: Two-Year Results from the Phase 3 nAMD Trials of Faricimab with T&E Dosing
• Aflibercept 8 mg in nAMD (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
• The real-world efficacy and safety of faricimab in nAMD: TRUCKEE study – 6 month results
• Review of real-world evidence of faricimab in nAMD and DME
• PULSAR: Intravitreal Aflibercept 8 mg in nAMD: 48-Week Results, Phase 3 Trial
• RGX-314: Gene Therapy for nAMD by Subretinal Delivery: Phase 1/2a Dose Escalation Study
• OPT-302: VEGF-C/D Inhibitor for nAMD: Phase 2b Trial
• OPTIC: Ixoberogene soroparvovec for nAMD: Phase 1 Study
• Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
• Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial
• Port delivery system with ranibizumab (Susvimo) recall: What does it mean to the retina specialists
• Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
• Suprachoroidal Delivery of RGX-314 Well-Tolerated in Wet AMD
• FDA approves faricimab for treatment of wet AMD, DME
• TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
• YOSEMITE and RHINE Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
• Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
• Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
• Port delivery system: a novel drug delivery platform to treat retinal diseases
• Review of gene therapies for age-related macular degeneration.
• Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES Study: A Randomized Clinical Trial
• Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease
• Faricimab shows efficacy, safety and durability in treatment of wet AMD
• Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records
• Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
• Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR
• Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
• Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
• End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
• Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
• Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
• Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
• What AREDS means for you?
• Mayo Clinic: Dry Macular Degeneration
• Understanding Your AMD – Patient Handout
• Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration – Patient Handout
• Results from the Phase 3 HAWK and HARRIER Studies
• Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education
• Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

Cataract and/or Refractive Surgery

• AAO Refractive Surgery Preferred Practice Patterns 2024
• Saving of Time Using a Software-Based versus a Manual Workflow for Toric Intraocular Lens Calculation and Implantation
• Application of artificial intelligence in cataract management: current and future directions
• Latest Development in Extended Depth-of-Focus Intraocular Lenses: An Update
• AAO Cataract in the Adult Eye Preferred Practice Pattern 2021
• Cataract and Refractive Lens Exchange Questionnaire
• Post-Refractive IOL Calculator
• American Society of Cataract and Refractive Surgery
• Physician Quality Reporting System Measures Associated with Cataract Surgery
• Toric IOL Calculator
• Preparing for Cataract Surgery – Postoperative Concerns – Patient Handout

Conjunctivitis

• Conjunctivitis (Pink Eye) Treatment
• Conjunctivitis: What is Pink Eye? – Patient Information
• Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout

Diabetic Macular Edema (DME)

• Diabetic Retinopathy Preferred Practice Pattern
• Long-term Treatment Patterns for DME: 6-Year Follow-Up in the IRIS® Registry
• YOSEMITE/RHINE: Results from the Phase 3 DME Trials of Faricimab with T&E Dosing
• Aflibercept 8 mg in DME (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
• PHOTON: Intravitreal Aflibercept 8 mg in DME: 48-Week Results, Phase 2/3 Trial
• KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema
• Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
• A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema: The European DME Registry Study
• Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study
• The Mechanism of the Bispecific Antibody Faricimab
• Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
• Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout
• Facts About Macular Edema
• 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study
• Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
• Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis
• Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States

Diabetic Retinopathy

• Retina Summary Benchmarks, 2023 (for Patients)
• Understanding Diabetic Retinopathy – Patient Handout
• Diabetic Retinopathy Clinical Research Network Publications
• Diabetic Retinopathy: Causes, Symptoms, Treatment
• PANORAMA: Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy
• Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
• Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy

Geographic Atrophy

• Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
• Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel
• Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3
• OAKS/DERBY: Pegcetacoplan for GA Secondary to AMD: Phase 3 Trials
• GATHER2: Avacincaptad pegol for GA: Phase 3 Trial
• Understanding Geographic Atrophy in Advanced Non-Exudative Age-Related Macular Degeneration: a Teaching Case Report
• Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
• Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
• Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study
• Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
• C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
• Prevalence and phenotype associations of complement factor I mutations in geographic atrophy
• Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study
• Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
• Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial

General

• ICD-10-CM for Ophthalmology
• EyeNet Magazine
• National Institutes of Health Guidelines on Human Subjects Research
• AAO Preferred Practice Patterns
• American Academy of Ophthalmology. Teleophthalmology: how to get started.
• Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet.
• Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
• AAO.org: Home Eye Test for Adults

Glaucoma

• CDC Vision Health Initiative: Facts About Glaucoma
• Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
• The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
• A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
• Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
• National Eye Institute: Glaucoma
• Advances in medical therapy for glaucoma
• New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
• Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
• Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
• 2 Year Experience with Latanoprostene Bunod in Clinical Practice
• Sustained-release drug delivery systems for the treatment of glaucoma
• Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
• Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
• Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results
• Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
• Bimatoprost Implant. Prescribing Information
• Microinvasive Glaucoma Surgery (MIGS)
• Xen Gel Stent: Directions for Use
• American Glaucoma Society
• Facts About Glaucoma

Inherited Retinal Diseases

• Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium
• Genetic testing and diagnosis of inherited retinal diseases
• AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2022
• Genetic testing for inherited retinal degenerations: Triumphs and tribulations
• Patient Information – Inherited Retinal Diseases
• Foundation Fighting Blindness

Macular Disorders

• Revised Definitions from the International Classification of Diseases of the Vitreomacular Interface
• Understanding Vitreomacular Traction Syndrome – Patient Handout
• Managing Challenging Macular Holes

Macular Telangiectasia

• Macular Telangiectasia Type 2: A Comprehensive Review

Neurotrophic Keratitis

• Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
• Cenegermin Prescribing Information
• Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
• Neurotrophic keratopathy: An updated understanding
• Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
• Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
• Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy
• Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
• Neurotrophic keratopathy: current challenges and future prospects
• Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
• Cenegermin: A Review in Neurotrophic Keratitis

Neuromyelitis Optica Spectrum Disorder (NMOSD)

• Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
• International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Recommendations for Eculizumab, Inebilizumab, and Satralizumab
• Contemporary management challenges in seropositive NMOSD
• Guthy Jackson Foundation
• Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
• Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
• AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in NMOSD
• Long-term efficacy and safety of inebilizumab in NMOSD: Analysis of AQP4-IgG seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
• Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
• Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder (SAkuraStar)
• Neuromyelitis Optica Spectrum Disorder
• The Sumaira Foundation for NMO

Ocular Surface and Lid Margin Disease

• Care of the Patient with Ocular Surface Disorders
• NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction
• TFOS Lifestyle: Impact of nutrition on the ocular surface
• Dry eye syndrome: comprehensive etiologies and recent clinical trials
• Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists
• Omega-3 fatty acids in the management of dry eye disease—An updated systematic review and meta-analysis
• A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
• Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
• Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
• Racial and Ethnic Disparities in Dry Eye Diagnosis and Care
• Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study
• Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study
• Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
• Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
• AAO EyeWiki: Meibomian Gland Dysfunction (MGD)
• NIH Dry Eye Patient Information
• Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
• Demodex and Eye Disease
• Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial
• A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
• Emerging therapies for dry eye disease
• AAO: Improved Dry Eye Drugs for 2022 and Beyond
• The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares
• New strategies for the management of ocular surface disease in glaucoma patients
• Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
• Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
• Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies
• Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
• Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
• Diseases of Ocular Surface
• Dry Eye: Patient Information
• American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
• American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
• Sjögren’s Syndrome Foundation

Presbyopia

• Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
• In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment
• Review of Presbyopia Treatment with Corneal Inlays and New Developments
• Safety and Efficacy of AGN-190584 in Individuals With Presbyopia The GEMINI 1 Phase 3 Randomized Clinical Trial
• 1.25% Pilocarpine for Presbyopia
• Potential new presbyopia treatments in development
• What Is Presbyopia? (Patient Material)
• A Review of Pharmacological Presbyopia Treatment
• Treatments for presbyopia coming soon

Retinal Vascular Diseases (RVO)

• Relationship Between Nerve Fiber Layer Hemorrhages and Outcomes in Central Retinal Vein Occlusion
• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study
• Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes
• Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
• Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
• Branch Retinal Vein Occlusion Information for Patients
• Central Retinal Vein Occlusion Information for Patients
• Understanding Your Retinal Vein Occlusion (RVO) – Patient Handout

Thyroid Eye Disease (TED)

• Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
• Teprotumumab-Related Hyperglycemia
• Thyroid Eye Disease: Navigating Diagnosis and Treatment
• Patient Brochures
• Navigating the New Treatment Landscape
• Graves’ Eye Disease: Patient Information from the American Thyroid Association
• Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment OPTIC-X Study
• Future Projections in Thyroid Eye Disease
• Patient Material: Examining the Optics of TED
• Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
• Therapeutic IGF-I receptor inhibition alters fibrocyteimmune phenotype in thyroid-associated ophthalmopathy
• Hearing Dysfunction After Treatment with Teprotumumab for Thyroid Eye Disease
• Teprotumumab for patients with active thyroid eye disease: pooled data analysis, subgroup analyses, andoff-treatment follow-up results
• Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists
• Audiology findings in patients with teprotumumab associated otologic symptoms
• Graves’ Disease: Patient Information
• Teprotumumab for the Treatment of Active Thyroid Eye Disease

Uveitis

• Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE)
• Real-Life Efficacy, Safety, and Use of Dexamethasone Intravitreal Implant in Posterior Segment Inflammation Due to Non-infectious Uveitis (LOUVRE 2 Study)
• Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review
• OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema
• Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis
• Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
• Preparing for Your Appointment – Patient Handout

Vitreoretinal Surgery

• Preparing for a Vitrectomy – Patient Handout